Analysis of drugs' use for the treatment of dementia in psychiatry

Abstract

BACKGROUND: The article provides an analysis of the prescriptions of a group of medications used for the prevention and treatment of dementia associated with central nervous system damage. During the period of gerontogenesis, irreversible changes occur in the human body, associated with the somatic state and mental processes in the CNS. According to the ICD-11 classification, this type of pathology is defined as neurocognitive disorders (6D80-86).

PURPOSE OF THE STUDY: Analysis of the prescription of drugs for the treatment of dementia in patients with disorders caused by neurocognitive changes due to the aging process.

MATERIALS AND METHODS: In the course of the study, the following were used: content analysis, observation method, documentary, systematic, statistical and other methods of analyzing drug prescriptions. The research base include the gerontological departments of the Sverdlovsk Regional Psychiatric Hospital. Medical documentation with the specified medications prescribed to patients aged 60 years and older with a psychiatric history.

RESULTS AND DISCUSSION: A trend has been established towards a decrease in the number of prescriptions of drugs No. 1–3, 7 (Galantamine, Memantine, Akineton and Vinpocetine, respectively) and an increase in No. 4–6 (aminophenylbutyric acid, rivastigmine, piracetam). The experts prefer drugs with nootropic effects (57% of the entire sample), which are used along with anticholinergics (14%) and anticholinesterase drugs (29%).

CONCLUSION: According to the results of the analysis, a high level of prescriptions by doctors of specialized departments have medicines numbered No. 4, 5, and 6 (aminophenylbutyric acid, rivastigmine, piracetam).

Keywords

analysis / cognitive disorders / dementia / nootropic effect / psychiatric spectrum

References

[1] Ostroumova OD, Starodubova AV, Ostroumova TM, Chernyaeva MS. Cognitive Disorders and Dementia in Old Patients With Arterial Hypertension. Kardiologiia. 2018;58(10):71–79. (In Russ.) EDN: YLGHJZ doi: 10.18087/cardio.2018.10.10186

[2] Остроумова О.Д., Стародубова А.В., Остроумова Т.М., Черняева М.С. Когнитивные нарушения и деменция у больных пожилого возраста с артериальной гипертонией // Кардиология. 2018. Т. 58, № 10. С. 71–79. EDN: YLGHJZ doi: 10.18087/cardio.2018.10.10186

[3] Ostroumova OD, Starodubova AV, Ostroumova TM, Chernyaeva MS. Cognitive Disorders and Dementia in Old Patients With Arterial Hypertension. Kardiologiia. 2018;58(10):71–79. (In Russ.) EDN: YLGHJZ doi: 10.18087/cardio.2018.10.10186

[4] Parfenov VA. Dementia. Clinical gerontology. 2006;12(11):3–10. (In Russ.) EDN: JUUINT

[5] Парфенов В.А. Деменция // Клиническая геронтология. 2006. Т. 12, № 11. С. 3–10. EDN: JUUINT

[6] Parfenov VA. Dementia. Clinical gerontology. 2006;12(11):3–10. (In Russ.) EDN: JUUINT

[7] Clinical recommendations of the Russian Federation of 2020. “Cognitive disorders in the elderly and senile”. Available from: https://cr.minzdrav.gov.ru/schema/617_1 (accessed: November 8, 2023). (In Russ.)

[8] Клинические рекомендации Российской Федерации от 2020 г. «Когнитивные расстройства у лиц пожилого и старческого возраста». Режим доступа: https://cr.minzdrav.gov.ru/schema/617_1 (дата обращения: 08.11.2023).

[9] Clinical recommendations of the Russian Federation of 2020. “Cognitive disorders in the elderly and senile”. Available from: https://cr.minzdrav.gov.ru/schema/617_1 (accessed: November 8, 2023). (In Russ.)

[10] Leonova MV. Deprescribing against polypharmacy: the possibilities of the method. Pharmateka. 2019;26(9):26–34. (In Russ.) EDN: ZJYEQP doi: 10.18565/pharmateca.2019.9.26-34

[11] Леонова М.В. Депрескрайбинг против полипрагмазии: возможности метода // Фарматека. 2019. Т. 26, № 9. С. 26–34. EDN: ZJYEQP doi: 10.18565/pharmateca.2019.9.26-34

[12] Leonova MV. Deprescribing against polypharmacy: the possibilities of the method. Pharmateka. 2019;26(9):26–34. (In Russ.) EDN: ZJYEQP doi: 10.18565/pharmateca.2019.9.26-34

[13] Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019;322(16):1589–1599. (In Russ.) doi: 10.1001/jama.2019.4782

[14] Arvanitakis Z., Shah R.C., Bennett D.A. Diagnosis and Management of Dementia: Review // JAMA. 2019. Vol. 322, N 16. P. 1589–1599. doi: 10.1001/jama.2019.4782

[15] Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019;322(16):1589–1599. (In Russ.) doi: 10.1001/jama.2019.4782

[16] Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169–182. doi: 10.1111/j.1527-3458.2005.tb00268.x

[17] Winblad B. Piracetam: a review of pharmacological properties and clinical uses // CNS Drug. Rev. 2005. Vol. 11, N 2. P. 169–182. doi: 10.1111/j.1527-3458.2005.tb00268.x

[18] Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169–182. doi: 10.1111/j.1527-3458.2005.tb00268.x

[19] Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618–628. doi: 10.1016/s1734-1140(11)70574-6

[20] Patyar S., Prakash A., Modi M., Medhi B. Role of vinpocetine in cerebrovascular diseases // Pharmacol. Rep. 2011. Vol. 63, N 3. P. 618–628. doi: 10.1016/s1734-1140(11)70574-6

[21] Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618–628. doi: 10.1016/s1734-1140(11)70574-6

[22] Zakharov NB, Zlokazova MV, Semakina NV. Gender factor and mental disorders. Vyatka Medical Bulletin. 2022;75(3):77–81. (In Russ.) EDN: YQIPEI doi: 10.24412/2220-7880-2022-3-77-81

[23] Захаров Н.Б., Злоказова М.В., Семакина Н.В. Гендерный фактор и психические расстройства // Вятский медицинский вестник. 2022. Т. 75, № 3. С. 77–81. EDN: YQIPEI doi: 10.24412/2220-7880-2022-3-77-81

[24] Zakharov NB, Zlokazova MV, Semakina NV. Gender factor and mental disorders. Vyatka Medical Bulletin. 2022;75(3):77–81. (In Russ.) EDN: YQIPEI doi: 10.24412/2220-7880-2022-3-77-81

RIGHTS & PERMISSIONS

Eco-Vector